BRISBANE, AUSTRALIA: Anteris Technologies Ltd (ASX: AVR) is considering to merge with NASDAQ-listed special purpose acquisition company Medicus Sciences Acquisition Corp. (MSAC).

MSAC currently has no commercial operations and was established as a blank cheque company for the purpose of, amongst other things, effecting a merger, share exchange or business combination with one or more businesses.

The proposed transaction is a business combination whereby all existing Anteris shareholders will receive shares in MSAC in exchange for their shares in the Company by MSAC, to be implemented via a court-approved scheme of arrangement (Proposal).

The proposal contemplates an issuance of new equity by MSAC in exchange for the current shares in the Company at an equivalent value and stipulates that post-transaction the merged entity would have a minimum of $50 million in cash, plus the existing funds held by the Company.

The board of Anteris Technologies is considering the proposal. There is no certainty at this time that the company will proceed with the proposal; a binding offer from MSAC will be forthcoming; or the proposal will result in any transaction occurring.

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is developing next-generation technologies that help healthcare professionals reproduce consistent life-changing outcomes for patients. www.anteristech.com